OpenAI launches GPT‑Rosalind

Biology research often means sorting through gene data, protein shapes, and lab results that can overwhelm general-purpose software. OpenAI said on April 16 it is rolling out GPT‑Rosalind, a model built specifically for that work. (openai.com) OpenAI said the model is designed for biochemistry, drug discovery, translational medicine, protein engineering, chemistry, and genomics. Reuters reported the name refers to Rosalind Franklin, the British scientist whose X-ray work helped reveal DNA’s structure. (openai.com) (reuters.com) The company is not releasing it as a mass-market chatbot. OpenAI said GPT‑Rosalind is in “research preview” and available through a trusted-access program for eligible institutions that apply for access. (openai.com) (help.openai.com) Drug discovery is a long screening process: researchers test biological targets, narrow hypotheses, and run experiments before a candidate ever reaches human trials. OpenAI said a new drug in the United States typically takes about 10 to 15 years from target discovery to regulatory approval. (openai.com) OpenAI is pitching the model at the earliest research stages, where scientists decide which genes, proteins, or pathways are worth pursuing. The company said gains there can improve target selection, biological hypotheses, and experiment quality downstream. (openai.com) The company’s help documentation says the model is meant for bioinformaticians, computational biologists, and early-discovery biologists, and that it is built for stronger tool use and database use across multi-step workflows. That means it is supposed to do more than answer questions in plain text; it is meant to work through chained research tasks. (help.openai.com) OpenAI framed the launch as part of a broader product push, not a one-off research demo. Its news page listed GPT‑Rosalind on April 16 alongside updates to cyber defense tools and the Agents software development kit, while ChatGPT release notes show continued model swaps and feature changes across the product. (openai.com) (help.openai.com) Those release notes show how quickly the company’s public products are shifting. OpenAI said GPT‑4o, GPT‑4.1, GPT‑4.1 mini, OpenAI o4‑mini, and GPT‑5 Instant and Thinking were retired from ChatGPT on February 13, 2026, even as newer GPT‑5.3 and GPT‑5.4 options rolled out. (help.openai.com 1) (help.openai.com 2) That leaves GPT‑Rosalind as a sign of where OpenAI wants to go next: narrower models for specialized work, released behind tighter controls than consumer ChatGPT. For now, the company is limiting access to institutions it says can use the system for “high-impact, beneficial research” with safeguards against misuse. (openai.com)